• Careers
  • Contact
  • Board of Directors

    John D. Mendlein, Ph.D.

    Executive Chairman

    Dr. Mendlein currently serves as CEO and executive chairman of aTyr Therapeutics and chairman for Fate Therapeutics.  He served as CEO of Adnexus Therapeutics until Bristol-Myers Squibb (BMY) purchased the company after the award-winning partnership between Adnexus and BMY.  Previously, Dr. Mendlein served as chairman and CEO at Affinium Pharmaceuticals, and he held a variety of roles, including board member, general counsel and chief knowledge officer, at Aurora Biosciences (acquired by Vertex Pharmaceuticals, VRTX).  He has worked as an attorney at Cooley LLP, a law firm, in its life sciences and technology litigation practice groups and as a scientist in the Department of Molecular Biology and Protein Expression at Smith Kline & French, now GlaxoSmithKline. He is currently an advisory board member of Genesys Capital, a founder and board member of Homes for Sudan, a non-profit in Boston, and a scientific advisory board member for Ocean Discovery Institute, a non-profit in San Diego.  He is the author or inventor of more than 30 publications and patents. Dr. Mendlein earned a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of Law and a B.S. in biology from the University of Miami.

    print email
    © 2007 - 2017   aTyr Pharma.   Legal   Privacy Policy